Abstract:Abstract Background Clostridioides difficile infection (CDI) is a frequent cause of flares in inflammatory bowel disease (IBD) and it is related to higher risk of colectomy and mortality. The incidence of CDI in IBD is higher than in the general population and it has increased in recent years. Biologic therapy could be risk factor for CDI, but the evidence is scarce. The aim of the study was to compare CDI incidence between IBD patients treated with anti-tumor necrosis factor (antiTNF) agents and VDZ. Secondary endpoints were outcomes related to CDI (hospital admission, intensive care monitoring, colectomy) and IBD (steroids requirement, switch of biologic therapy, surgery). Methods Retrospective observational multicenter study conducted in 23 Spanish hospitals, promoted by GETECCU, including patients with ulcerative colitis or Crohn’s disease with colonic involvement who had CDI after complete induction of antiTNF (group 1) or VDZ (group 2) between 2018 and 2021. Hospitals also provided the total number of patients who initiated antiTNF or VDZ during that period. The chi-square test was used to compare categorical variables, and the Mann–Whitney U-test to compare quantitative variables. Results A total of 3860 IBD patients with antiTNF treatment and 780 with VDZ were reviewed. 63 patients with CDI were identified: 45 in group 1 and 18 in group 2. Incidence of CDI was statistically higher in group 2 than in group 1 (2.3% vs 1.2% respectively; p=0.01). Baseline characteristics of patients with CDI in both groups are shown in Table 1. Risk factors for CDI (chronic kidney failure, hospitalization, previous antibiotic usage, previous CDI) were distributed similarly between groups, except proton pump inhibitor treatment (35.6% in group 1 vs 76.5% in group 2; p=0.01). No significant differences in the evolution of CDI were found between groups. Hospital admission rate was 53.3% in group 1 and 27.8% in group 2 (p=0.09). None required intensive care or colectomy caused by CDI. Recurrent CDI (within 8 weeks) occurred in 8.9% in group 1 and 11.1% in group 2 (p=0.79). Outcomes of IBD were similar between groups, regarding steroid treatment (51.1% in group 1 vs 50% in group 2; p=0.94) and switch of biologic therapy (37.8% in group 1 vs 50% in group 2; p=0.37). During follow-up, there was 1 case (group 1) of perforation in the 1st month and 5 patients (4 in group 1; 1 in group 2) required surgery for medically refractory disease between the 3rd and 6th month. One patient (group 1) died (non-IBD or CDI-related cause). Conclusion Incidence of CDI was higher during VDZ therapy compared with antiTNF. The evolution of CDI and IBD tends to be similar between groups. More data are needed to consider VDZ as a risk factor of CDI.

Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient

A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

Outcomes after Fecal Microbiota Transplantation in combination with Bezlotoxumab for Inflammatory Bowel Disease and Recurrent C. difficile Infection

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

S3935 Recurrent Clostridioides difficile Infection in Crohn's Disease: A Case Series

S1045 Fecal Microbiota Transplantation (FMT) With Bezlotoxumab Was Not Better Than FMT Alone in Inflammatory Bowel Disease Patients and Recurrent Clostridioides difficile Infection: Results from a Randomized Controlled Trial

Fidaxomicin versus oral vancomycin for Clostridioides difficile infection among patients at high risk for recurrence based on real-world experience

SER-109 (VOWSTTM): A Review in the Prevention of Recurrent Clostridioides difficile Infection

Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO study

Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non- Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study

P829 Clostridioides difficile infection in patients using vedolizumab and antiTNF: incidence and consequences (CDIFVEDO study of GETECCU)

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice

A randomized controlled trial of efficacy and safety of Fecal Microbiota Transplant for preventing recurrent Clostridioides difficile infection

Comparing rates of recurrent infection for first occurrence of Clostridioides difficile between tapered oral vancomycin and standard vancomycin: a retrospective, propensity matched cohort study

Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA®) for Preventing Recurrent Clostridioides difficile Infection

Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection

CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection

Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA ® ) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection

The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection